Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 Targeted T Cells in Advanced Oesophagogastric Cancer
2012-005327-33Phase 2Terminated
- Sponsor
- The Christie
- Start
- Jul 2013
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NYESO T cells in esophagogastric junction cancer, sponsored by The Christie. Primary endpoint: Objective response rate by RECIST. Started Jul 2013; status: terminated.
02
Drugs
NYESO T cells
03
Conditions
esophagogastric junction cancer
Beyond the preview
Go deeper on 2012-005327-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005327-33.